Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide Monotherapy in HIV-Positive Individuals With Kaposi Sarcoma in Sub-Saharan Africa
NCT03601806Phase 2Completed
- Sponsor
- AIDS Malignancy Consortium
- Start
- Apr 2021
- Primary completion
- Nov 2024
- Modality
- Molecular Glues
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of pomalidomide in Kaposi sarcoma (KS), sponsored by AIDS Malignancy Consortium. Primary endpoints: Overall Response Rate at 48 weeks, Complete Response Rate at 48 weeks and 1 more. Started Apr 2021; status: completed.
02
Drugs
pomalidomide
03
Conditions
Kaposi sarcoma (KS)
Beyond the preview
Go deeper on NCT03601806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03601806.